Editorial Commentary: Third-Generation Autologous Chondrocyte Implantation-Are Cells Seeded Onto the Scaffold Itself in It for the Long Run?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32624127.
- Also identified by DOI 10.1016/j.arthro.2020.05.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Autologous chondrocyte implantation (ACI) is an increasingly performed procedure, with rapidly evolving technology. First-generation ACI used a periosteal patch, leading to the second generation, in which a type I-type III collagen membrane is used to cover the autologous chondrocytes, and ultimately the third generation, in which autologous chondrocytes are seeded onto the scaffold itself. As third-generation, scaffold-based ACI techniques are becoming more widely available, interest in the long-term clinical and radiographic outcomes continues to grow, especially given the high costs associated with these procedures. Several studies have now shown persistently improved clinical outcomes at long-term follow-up, which support the increasing utilization of third-generation ACI techniques. However, it is important to continue to develop our understanding of the limitations of and expectations with third-generation ACI, particularly regarding reoperation, as well as to continue to design high-quality long-term studies that can evaluate differences in technology.
Medical subject headings
- Cartilage, Articular
- Chondrocytes